AstraZeneca PLC (AZN) Stock: Rebounds as Enhertu Lung Cancer Trial Boosts Shares
TLDR
-
AstraZeneca stock rises after positive Enhertu Phase 3 lung cancer results.
-
Enhertu improves progression-free survival against current first-line care.
-
DESTINY-Lung04 supports Enhertu’s move into earlier lung cancer treatment use.
-
The Phase 3 trial enrolled 454 patients across Asia, Europe and North America.
-
AstraZeneca plans to share trial data with regulators and medical meetings.
AstraZeneca (AZN) shares rebounded in pre-market trading after the company reported positive results from its DESTINY-Lung04 Phase 3 lung cancer trial. AZN stock rose 0.52% to $157.27 after closing 0.50% lower at $156.45. The results strengthened AstraZeneca’s oncology outlook as Enhertu showed a clear benefit against the current first-line treatment standard.
AstraZeneca Stock Gains After DESTINY-Lung04 Results
AstraZeneca reported that Enhertu produced a statistically significant improvement in progression-free survival during the DESTINY-Lung04 study. The trial compared Enhertu with platinum-pemetrexed chemotherapy combined with pembrolizumab in patients with advanced HER2-mutant lung cancer. Therefore, the results support Enhertu’s potential expansion into an earlier treatment setting for eligible patients.
… Continue reading the full article at the original source below.
